CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 205 enrolled
Drug / intervention
Metoclopramide Nasal Spray +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02025725
NCT02025725Phase 3Completed

Phase 3 Study of Intranasal Metoclopramide in Women With Symptomatic Diabetic Gastroparesis

Evoke Pharma·interventional·Posted Jan 1, 2014·Updated Jul 7, 2020

In Brief

A Phase 3 clinical trial evaluating Metoclopramide Nasal Spray and Placebo Nasal Spray for Diabetic Gastroparesis. Completed, enrolled 205 participants across 50 sites.

Detailed Summary

The purpose of this study is provide confirmation of the safety and efficacy of Metoclopramide Nasal Spray compared to placebo in reducing the symptoms of diabetic gastroparesis in adult women.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJan 1, 2014
Enrollment StartMar 27, 2014
Primary CompletionMay 27, 2016
Study CompletionJun 27, 2016
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 12.5 years ago

Interventions

Metoclopramide Nasal Spraydrug

nasal spray formulation of metoclopramide

Placebo Nasal Spraydrug

nasal spray formulation with vehicle only